Cash/Burn From SEC Filing For Period: 

Q1 '20

VKTX

Viking Therapeutics

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.

Cash

$269.2M

Burn Rate

-$9.7M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

VK0612

Type 2 Diabetes

Phase 2 TBA

TBD

VK5211 (SARM)

Hip Fracture, Muscle Wasting

Phase 3 TBA

TBD

VK2809

Non-Alcoholic Fatty Liver Disease (NAFLD)

Phase 2 (Efficacy Data at EASL)

August 28, 2020

VK2809

NASH

Phase 2

TBD

VK1430

High Triglycerides, NASH

Pre-Clinical

TBD

VK0214

X-ALD

Phase 1 (Results)

TBD

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon